Abraxane Inventor Puts Money to Work in Sorrento
Research - On Monday, Sorrento announced that Dr. Patrick Soon-Shiong made a $41 million investment in the company and now owns 19.9% of Sorrento.
PremiumSearch Results for gene therapy
Sorrento’s New Investor Isn’t JUST a Billionaire
Insights - Investor/entrepreneur Dr. Patrick Soon-Shiong is making a sizable investment in Sorrento Therapeutics (SRNE), in addition to forming a joint venture with the small company to develop … Continue Reading
Read now
Checkpoint Inhibitors: What are They and One Compelling Small-Cap Player
Research - Immune checkpoint regulators are again making headlines, this time at the American Society of Hematology, where they are demonstrating exciting early efficacy in hematological malignancies. … Continue Reading
Read now
Puma Biotech’s Delay Increases Headline Risk in 2016
Insights - Puma Biotech (PBYI) on Tuesday evening announced a significant, unexpected delay in its timeline for filing a New Drug Application with the FDA for lead … Continue Reading
Read now
All Hallow’s Eve but October Has Already Been Downright Spooky
Recap - Despite this asset class having just entered human testing, there’s significant excitement surrounding the therapeutic potential of blocking CD47 and the “DO NOT EAT” signal … Continue Reading
Read now
Esperion One-Ups Rival Cholesterol Drug in Midstage Study
Insights - Esperion Therapeutics Inc (ESPR) hit a home run with top-line results from ETC-1002-008, a 12-week Phase 2b study that is one of the largest ever … Continue Reading
Read now
Merrimack and Baxter Tie Up for Pancreatic Cancer Drug
Insights - Merrimack Pharmaceuticals (NASDAQ:MACK) and Baxter (NYSE:BAX) have climbed into bed on MM-398, Merrimack’s drug candidate for the treatment of metastatic pancreatic cancer, in a licensing deal worth … Continue Reading
Read now